Ulland Investment Advisors LLC Has $1.39 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Ulland Investment Advisors LLC lessened its stake in Boston Scientific Co. (NYSE:BSX) by 2.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,519 shares of the medical equipment provider’s stock after selling 420 shares during the quarter. Boston Scientific comprises about 0.9% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 22nd largest holding. Ulland Investment Advisors LLC’s holdings in Boston Scientific were worth $1,386,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. AE Wealth Management LLC raised its holdings in Boston Scientific by 18.9% in the second quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock worth $1,252,000 after purchasing an additional 2,582 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Boston Scientific by 71.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 333,963 shares of the medical equipment provider’s stock valued at $25,718,000 after purchasing an additional 139,392 shares during the period. Summit Trail Advisors LLC raised its holdings in Boston Scientific by 15.0% during the 2nd quarter. Summit Trail Advisors LLC now owns 10,767 shares of the medical equipment provider’s stock worth $829,000 after buying an additional 1,403 shares during the period. ProShare Advisors LLC increased its position in shares of Boston Scientific by 8.2% during the second quarter. ProShare Advisors LLC now owns 216,039 shares of the medical equipment provider’s stock worth $16,637,000 after acquiring an additional 16,430 shares in the last quarter. Finally, Frank Rimerman Advisors LLC boosted its stake in Boston Scientific by 29,986.6% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 20,158 shares of the medical equipment provider’s stock worth $1,552,000 after purchasing an additional 20,091 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares in the company, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock valued at $2,702,261 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $98.73 on Tuesday. The firm has a 50 day moving average of $91.00 and a 200-day moving average of $84.60. Boston Scientific Co. has a 12 month low of $59.85 and a 12 month high of $99.14. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $145.52 billion, a PE ratio of 81.60, a PEG ratio of 2.48 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company’s revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. On average, equities research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BSX shares. Evercore ISI upped their price target on Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Wells Fargo & Company increased their price target on shares of Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Citigroup raised their price objective on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $97.26.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.